DDInter1295 DDInter1676
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nimodipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nimodipine {u} (Compound) binds {v} (Gene) CACNB3
Nimodipine {u} (Compound) upregulates {v} (Gene) WIF1
Nimodipine {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Nimodipine {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Nimodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Nimodipine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Nimodipine (Compound) resembles Nisoldipine (Compound)
Nimodipine (Compound) binds CACNB3 (Gene)
Nimodipine (Compound) upregulates WIF1 (Gene)
Nimodipine (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class)
Nimodipine (Compound) causes Hyperhidrosis (Side Effect)
Nimodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Nimodipine may lead to a major life threatening interaction when taken with Clarithromycin